Prognose

Das durchschnittliche Kursziel der Analysten beträgt +1,77€(−23,71%). Der Median liegt bei +1,77€(−23,71%).

Kaufen	4
Halten	0
Verkaufen	0

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

News

NRx Pharmaceuticals, Inc. (NRXP) Q1 2025 Earnings Call Transcript
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Matthew Duffy – Chief Business Officer Jonathan Javitt – Founder, Chairman, and Chief Executive Officer Michael Abrams – Chief Financial Officer Conference Call Participants Tom Shrader – BTIG Ed Woo – Ascendiant Capital Operator Good afternoon, ladies and gentlemen, and welcome to the NRx Pharmaceuticals First Quarter 2025 Earnings Call. At this time, all lines are in a listen-only mode.» Mehr auf seekingalpha.com
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports First Quarter 2025 Financial Results and Provides Corporate Update
Company has continued to advance its previously announced plan to obtain FDA approval for two new drugs and to develop a network of clinics focused on neuroplastic therapies to treat severe and suicidal depression, PTSD, and related conditions. Clinic acquisition financing is at the HOPE Therapeutics level and non-dilutive to NRXP shareholders In January 2025 completed the third tranche of a convertible note offering and registered direct equity offering to an institutional investor on favorable terms to the Company; expected to provide sufficient cash to support operations through the end of 2025.» Mehr auf prnewswire.com
HOPE Therapeutics, Inc. a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Signing of Term Sheet for $7.8 Million Debt Financing to Fuel HOPE Clinic Acquisitions
Term sheet with Universal Capital, LLC to fund HOPE Therapeutics clinic acquisition strategy Funding tied to already-announced acquisitions, with additional tranches contemplated for further growth, subject to standard due diligence Together with previously announced term sheet with a strategic investor, HOPE funding of $10.3 million is planned in the near term MIAMI , May 15, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc. ("HOPE"), a multi-site clinical care delivery organization and wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, today announced signing of a term sheet with Universal Capital, LLC ("Universal") to provide $7.8 million in acquisition capital to initiate HOPE's planned national rollup of interventional psychiatry clinics, commencing with previously-announced acquisitions of Dura Medical, Kadima, and NeuroSpa. Together with proceeds of a previously announced strategic investment, this financing is anticipated to provide $10.3 million in acquisition capital.» Mehr auf prnewswire.com

Unternehmenszahlen

Im letzten Quartal hatte BIG ROCKPAR einen Umsatz von 0,00€ und ein Nettoeinkommen von −5,10 Mio€

(EUR)	März 2025	YOY
Umsatz	0,00	-
Bruttoeinkommen	0,00	100,00%
Nettoeinkommen	−5,10 Mio	15,77%
EBITDA	−3,56 Mio	39,05%

Fundamentaldaten

Metrik	Wert
Marktkapitalisierung	+39,68 Mio€
Anzahl Aktien	17,29 Mio
52 Wochen-Hoch/Tief	+5,31€ - +0,97€
Dividenden	Nein
Beta	1,45
KGV (PE Ratio)	−1,77
KGWV (PEG Ratio)	−0,11
KBV (PB Ratio)	−1,70
KUV (PS Ratio)	+11.237,98

Unternehmensprofil

NRX Pharmaceuticals, Inc. ist ein pharmazeutisches Unternehmen in der klinischen Phase und entwickelt neuartige Therapeutika für die Behandlung von Erkrankungen des zentralen Nervensystems und lebensbedrohlichen Lungenkrankheiten. Zu seinen Produkten gehören ZYESAMI, ein Prüfpräparat, das eine klinische Studie der Phase IIb/III zur Behandlung von COVID-19-bedingtem Atemversagen abgeschlossen hat, sowie die oralen Therapeutika NRX-100 und NRX-101 zur Behandlung bipolarer Depressionen bei Patienten mit akuter Suizidalität und subakuten Suizidgedanken und -verhaltensweisen. Das Unternehmen wurde im Jahr 2015 gegründet und hat seinen Sitz in Wilmington, Delaware.